22ND CENTURY GROUP INC
XXIINASDAQTrading Snapshot
- Day Range
- $0.82 – $0.83
- 52-Week Range
- $1.15 – $646.40
- Volume
- $3.90B
- Avg Volume
- $2.80B
- Shares Outstanding
- 350,000
- Next Earnings
- Nov 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $3M
- P/E Ratio
- —
- P/S Ratio
- 0.0x
- EPS (TTM)
- $221.66
- Dividend Yield
- —
- Dilution (1yr)
- +40579.3%
Why Investors Own XXII
- ✓High-growth profile — revenue up +51.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
22ND CENTURY GROUP INC
XXII
StockOtter · stockotter.spaceAbout 22ND CENTURY GROUP INC
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
22nd Century Group's Reduced-Nicotine Tobacco Platform Positioned to Support France's Nicotine-Reduction Initiative
Independent French health agency ANSES recommends a maximum nicotine limit for all combustible tobacco product; the Company's supply now includes non-GMO reduced-nicotine tobacco, addressing a key feasibility question fo
22nd Century Group Urges Policymakers and FDA to Enact and Implement the Reduced Nicotine Content Standard, Citing Years Without a Final Rule
22 nd Century Group Calls on HHS Secretary Kennedy, Acting FDA Commissioner Diamantas and CTP Director Koplow to Enact and Implement the Reduced Nicotine Content Standard
22nd Century CEO & Chairman Larry Firestone: Improved Gross Margin, ~5,000 Retail Outlets and >$50B Market Opportunity Highlight Mid-Year Stockholder Letter
VLN ® Category Leader Accelerates 2H 2026 Growth Phase as Same-Store Sales Climb 22nd Century Accelerates 2H 2026 Commercial Execution MOCKSVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq
22nd Century Group to Participate in the HC Wainwright Conference on September 15, 2026
MOCKSVILLE, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven
22nd Century Group, Inc. (XXII) Q2 2026 Earnings Call Prepared Remarks Transcript
22nd Century Group, Inc. (XXII) Q2 2026 Earnings Call Prepared Remarks Transcript
22nd Century Group Reports Second Quarter 2026 Financial Results
Advances VLN ® Commercialization Through Expanded Retail Support and Brand-Building Initiatives